Name: Name:Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-, hydrochloride (1
Brand: Angene
SKU: AG00ECG9
Rating: 90 (10 reviews)

Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-, hydrochloride (1

CAS No.:

613677-28-4

Catalog Number:

AG00ECG9

Molecular Formula:

C19H19ClF3N3O2

Molecular Weight:

413.8213

Pack Size

Purity

Availability

Location

Price(USD)

Quantity

Product Description

Catalog Number:

AG00ECG9

Chemical Name:

Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-, hydrochloride (1

CAS Number:

613677-28-4

Molecular Formula:

C19H19ClF3N3O2

Molecular Weight:

413.8213

MDL Number:

MFCD30377209

IUPAC Name:

2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide;hydrochloride

InChI:

InChI=1S/C19H18F3N3O2.ClH/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22;/h2-4,9-11H,5-8H2,1H3,(H,23,24,27);1H

InChI Key:

YBTPRLDGGGYWIP-UHFFFAOYSA-N

SMILES:

CN1CCC(CC1)C(=O)c1cccc(n1)NC(=O)c1c(F)cc(cc1F)F.Cl

EC Number:

947-092-7

Properties

Complexity:

530

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

413.112g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

413.825g/mol

Monoisotopic Mass:

413.112g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

62.3A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

Literature

Title	Journal
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.	The journal of headache and pain 20120601
Defining and refining 5-HT receptor targets for migraine.	The Lancet. Neurology 20120501
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.	The Lancet. Neurology 20120501
Molecule of the month. Lasmiditan hydrochloride.	Drug news & perspectives 20100901